<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01910519</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT HIPC: VAX-010</org_study_id>
    <secondary_id>1U19AI090023-01</secondary_id>
    <nct_id>NCT01910519</nct_id>
  </id_info>
  <brief_title>Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)</brief_title>
  <official_title>Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without AS03 Adjuvant (HIPC: VAX-010)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the different immune responses to Influenza A (H5N1) Virus Monovalent
      Vaccine with and without the AS03 adjuvant. The Influenza A (H5N1) Virus Monovalent Vaccine
      with AS03 adjuvant vaccine is approved for use for adults to protect against flu caused by
      the A/H5N1 &quot;bird flu&quot; virus in Europe but none of the vaccines to be used in the study are
      approved for use in the United States. The results of this study will help researchers learn
      about better ways to vaccinate people against the H5N1 flu.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The influenza virus (a germ) causes influenza or &quot;flu.&quot; The flu is an infection of the
      breathing tubes and the lungs. In recent years, flu viruses that at first only infected birds
      have begun to infect humans. One of these strains is called avian influenza (A/H5N1 subtype)
      or &quot;bird flu&quot;. Although no human cases of bird flu have been diagnosed in the United States,
      this strain has caused severe illness and death in several hundred people since late 2003. .

      Vaccination is the most effective way of controlling flu and preventing its illness and
      complications. Vaccines help prevent illness by causing the body to make antibodies that
      fight infection. One way to improve the effectiveness of a vaccine is to include a substance
      that can stimulate the immune system to make more antibodies. This type of substance is
      called an adjuvant; one type of adjuvant is called AS03 (Adjuvant System 03).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</measure>
    <time_frame>Day 1</time_frame>
    <description>To identify innate immune signatures; 1 day post first vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</measure>
    <time_frame>Day 3</time_frame>
    <description>To identify innate immune signatures; 3 days post first vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</measure>
    <time_frame>Day 7</time_frame>
    <description>To identify innate immune signatures; 7 days post first vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</measure>
    <time_frame>Day 22</time_frame>
    <description>To identify innate immune signatures; 1 day post second vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</measure>
    <time_frame>Day 24</time_frame>
    <description>To identify innate immune signatures; 3 days post second vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</measure>
    <time_frame>Day 28</time_frame>
    <description>To identify innate immune signatures; 7 days post second vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Hemagglutination Inhibition Assay (HAI) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</measure>
    <time_frame>Day 21</time_frame>
    <description>To measure selective adaptive immune response; 21 days post first vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Microneutralization (MN) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</measure>
    <time_frame>Day 21</time_frame>
    <description>To measure selective adaptive immune response; 21 days post first vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Hemagglutination Inhibition Assay (HAI) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</measure>
    <time_frame>Day 42</time_frame>
    <description>To measure selective adaptive immune response; 21 days post second vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Microneutralization (MN) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</measure>
    <time_frame>Day 42</time_frame>
    <description>To measure selective adaptive immune response; 21 days post second vaccination</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Influenza A Virus, H5N1 Subtype</condition>
  <arm_group>
    <arm_group_label>H5N1 vaccine plus AS03 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H5N1 vaccine plus AS03 adjuvant: Influenza A Vaccine with AS03 adjuvant
Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H5N1 vaccine without adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H5N1 vaccine without adjuvant: Influenza A Vaccine without AS03 adjuvant
Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H5N1 vaccine plus AS03 adjuvant</intervention_name>
    <description>Administered vaccine: [GlaxoSmithKline] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.
Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart.</description>
    <arm_group_label>H5N1 vaccine plus AS03 adjuvant</arm_group_label>
    <other_name>Q-Pan H5N1</other_name>
    <other_name>adjuvanted Q-Pan H5N1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H5N1 vaccine without adjuvant</intervention_name>
    <description>Administered vaccine: [GlaxoSmithKline] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.
Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart.</description>
    <arm_group_label>H5N1 vaccine without adjuvant</arm_group_label>
    <other_name>unadjuvanted H5N1 vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals in good health (as determined by vital signs, medical history, physical
             examination and laboratory tests);

          -  Able to understand and give informed consent;

          -  Women of childbearing potential must agree to practice adequate contraception 1 month
             prior to study entry and until day 100 of the study.

        Exclusion Criteria:

          -  Personal or family history of sleeping disorders including any of the following:
             Narcolepsy with or without cataplexy; Idiopathic Hypersomnia or excessive daytime
             sleepiness of unknown origin; Sleep paralysis; Sleep related hallucinations
             (hypnagogic or hypnopompic hallucinations);

          -  Human leukocyte antigen (HLA)-DQB1*06:02 positivity (or DQB1*06 positivity if high
             resolution HLA testing cannot be performed);

          -  An abnormal erythrocyte sedimentation rate at baseline;

          -  Receipt of blood products 3 months prior to study entry and until day 100 of the
             study;

          -  Volunteers who donated blood 56 days before screening and have plans to donate on or
             before day 100 of the study;

          -  Hemoglobin value of less than 12 mg/dL for females and less than 13 mg/dL for males;

          -  A positive result in the Narcolepsy Mini Screen questionnaire;

          -  A score of ≥11 on the Epworth sleepiness scale questionnaire;

          -  Receipt of any experimental agents within 6 weeks prior to first vaccination and until
             the completion of the study;

          -  Receipt of any licensed live vaccine within 4 weeks or any licensed inactivated
             vaccine within 2 weeks prior to the first study vaccination or planned receipt of any
             vaccine within 42 days after study entry;

          -  Receipt of a H5 vaccine or AS03-adjuvanted vaccine at any time in the past prior to
             current study or have a history of A/H5N1 infection;

          -  Influenza-like illness (ILI) or documented influenza infection during the 2013-2014
             influenza season. [Not excluded from the study, volunteers with prior upper
             respiratory infections other than ILI];

          -  Chronic medical problems including (but not limited to) insulin dependent diabetes,
             severe heart disease, severe lung disease, severe liver disease, severe kidney
             disease, autoimmune disease, severe gastrointestinal disease;

          -  Alcohol or drug abuse and psychiatric conditions that in the opinion of the
             investigator would preclude compliance with the trial or interpretation of safety or
             endpoint data;

          -  Impaired immune function or chronic infections including (but not limited to) HIV,
             hepatitis B or C; organ transplant; active cancer or any history of hematologic
             cancer; receipt of chemotherapy, radiation therapy (past 36 months) or any other
             potentially immunosuppressive therapy [i.e. Systemic steroids at any dose and
             intra-articular administration of steroids in the past 3 months; (Nasal and topical
             steroids are allowed)], congenital immunodeficiency, anatomical or functional
             asplenia;

          -  Heart rate less than 40 bpm or greater than 100 bpm. Systolic blood pressure is less
             than 90 mm Hg or equal or greater than 160 mm Hg. Diastolic blood pressure is less
             than 60 mm Hg or equal or greater than 100 mg Hg;

          -  Pregnancy or postpartum (less than 1 year after delivery) or breast feeding;

          -  Severe reactions to prior vaccination with influenza virus vaccines, including
             anaphylaxis;

          -  History of Guillain-Barré syndrome;

          -  A previous sudden life-threatening allergic reaction to any ingredient of Influenza A
             (H5N1) Virus Monovalent Vaccine with or without AS03 adjuvant or to any of the
             substances that may be present in trace amounts such as thiomersal, egg residues
             including ovalbumin as well as residual amounts of sodium deoxycholate detergent,
             formaldehyde and sucrose;

          -  Volunteers with any acute illness, including any fever (&gt; 100.4 F [&gt; 38.0 C],
             regardless of the route) within 3 days prior to study entry;

          -  Social, occupational, or any other condition that in the opinion of the investigator
             might interfere with compliance with the study and vaccine evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine Rouphael, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hope Clinic, Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hope Clinic - Emory Vaccine Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <results_first_submitted>January 2, 2019</results_first_submitted>
  <results_first_submitted_qc>January 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2019</results_first_posted>
  <disposition_first_submitted>December 24, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>December 24, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 13, 2015</disposition_first_posted>
  <last_update_submitted>January 25, 2019</last_update_submitted>
  <last_update_submitted_qc>January 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza A (H5N1) virus</keyword>
  <keyword>H5N1 influenza</keyword>
  <keyword>influenza A/H5/N1</keyword>
  <keyword>monovalent H5N1 influenza vaccine</keyword>
  <keyword>systems biology</keyword>
  <keyword>AS03 adjuvant</keyword>
  <keyword>unadjuvanted</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with or without AS03 adjuvant undergoing scheduled anterior cruciate ligament (ACL) surgery at the Hope Clinic - Emory Vaccine Center in Decatur, Georgia. Participants were enrolled between July 2013 and January 2014.</recruitment_details>
      <pre_assignment_details>Of the 99 screened participants, 50 were enrolled and vaccinated. 2 participants withdrew from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
          <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
        </group>
        <group group_id="P2">
          <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
          <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
          <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
        </group>
        <group group_id="B2">
          <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
          <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
        <description>To identify innate immune signatures; 1 day post first vaccination</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
          <description>To identify innate immune signatures; 1 day post first vaccination</description>
          <units>differentially expressed genes (DEGs)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1434"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Downregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1768"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
        <description>To identify innate immune signatures; 3 days post first vaccination</description>
        <time_frame>Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
          <description>To identify innate immune signatures; 3 days post first vaccination</description>
          <units>differentially expressed genes (DEGs)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="654"/>
                    <measurement group_id="O2" value="787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Downregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445"/>
                    <measurement group_id="O2" value="620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
        <description>To identify innate immune signatures; 7 days post first vaccination</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
          <description>To identify innate immune signatures; 7 days post first vaccination</description>
          <units>differentially expressed genes (DEGs)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Downregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
        <description>To identify innate immune signatures; 1 day post second vaccination</description>
        <time_frame>Day 22</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
          <description>To identify innate immune signatures; 1 day post second vaccination</description>
          <units>differentially expressed genes (DEGs)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1953"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Downregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2820"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
        <description>To identify innate immune signatures; 3 days post second vaccination</description>
        <time_frame>Day 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
          <description>To identify innate immune signatures; 3 days post second vaccination</description>
          <units>differentially expressed genes (DEGs)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Downregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="487"/>
                    <measurement group_id="O2" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
        <description>To identify innate immune signatures; 7 days post second vaccination</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A Vaccine With and Without AS03 Adjuvant</title>
          <description>To identify innate immune signatures; 7 days post second vaccination</description>
          <units>differentially expressed genes (DEGs)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Downregulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Hemagglutination Inhibition Assay (HAI) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</title>
        <description>To measure selective adaptive immune response; 21 days post first vaccination</description>
        <time_frame>Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Hemagglutination Inhibition Assay (HAI) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</title>
          <description>To measure selective adaptive immune response; 21 days post first vaccination</description>
          <units>IU/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.561" lower_limit="4.976" upper_limit="6.213"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Microneutralization (MN) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</title>
        <description>To measure selective adaptive immune response; 21 days post first vaccination</description>
        <time_frame>Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Microneutralization (MN) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</title>
          <description>To measure selective adaptive immune response; 21 days post first vaccination</description>
          <units>IU/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.18" lower_limit="23.08" upper_limit="39.47"/>
                    <measurement group_id="O2" value="10.44" lower_limit="9.522" upper_limit="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Hemagglutination Inhibition Assay (HAI) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</title>
        <description>To measure selective adaptive immune response; 21 days post second vaccination</description>
        <time_frame>Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Hemagglutination Inhibition Assay (HAI) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</title>
          <description>To measure selective adaptive immune response; 21 days post second vaccination</description>
          <units>IU/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" lower_limit="26.19" upper_limit="65.12"/>
                    <measurement group_id="O2" value="5.183" lower_limit="4.919" upper_limit="5.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Microneutralization (MN) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</title>
        <description>To measure selective adaptive immune response; 21 days post second vaccination</description>
        <time_frame>Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
            <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Microneutralization (MN) Titers With Influenza A Vaccine With and Without AS03 Adjuvant</title>
          <description>To measure selective adaptive immune response; 21 days post second vaccination</description>
          <units>IU/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523.3" lower_limit="354.5" upper_limit="772.5"/>
                    <measurement group_id="O2" value="22.78" lower_limit="13.46" upper_limit="38.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Correlation of vaccine-induced blood transcription modules (BTMs) M183-TBA at day 1 with MN titers at day 42</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0039</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Correlation of vaccine-induced blood transcription modules (BTMs) M115-cytokines-receptors cluster at day 1 with MN titers at day 42</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0368</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Correlation of vaccine-induced blood transcription modules (BTMs) M74-transcriptional targets of glucocorticoid receptor at day 1 with MN titers at day 42</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0465</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Correlation of vaccine-induced blood transcription modules (BTMs) M58-B cell development/activation at day 1 with MN titers at day 42</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0411</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Correlation of vaccine-induced blood transcription modules (BTMs) M114.0-TBA at day 1 with MN titers at day 42</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0067</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 - Day 7 after 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine with or without AS03 adjuvant given 21 days apart.</time_frame>
      <desc>Local and systemic reactogenicity after receipt of each vaccine</desc>
      <group_list>
        <group group_id="E1">
          <title>Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant</title>
          <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant</description>
        </group>
        <group group_id="E2">
          <title>Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv</title>
          <description>Participants randomized to receive Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Missed abortion (unrelated to study vaccine)</sub_title>
                <description>Missed abortion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Body ache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal calculi</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nadine Rouphael MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-712-1435</phone>
      <email>nroupha@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

